REGISTERED NUMBER: 07254808 (England and Wales)

Unaudited Financial Statements for the Year Ended 31 January 2025

for

Naspram Pharma Limited

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

4

DIRECTOR:

Mr S M Patel

SECRETARY:

Mrs S Patel

REGISTERED OFFICE:

110 Carlton Avenue East

Wembley

Middlesex

HA9 8LY

REGISTERED NUMBER:

07254808 (England and Wales)

ACCOUNTANTS:

MohanRed & Co

110 Carlton Avenue East

Wembley

Middlesex

HA9 8LY

FIXED ASSETS

Intangible assets

4

-

-

Tangible assets

5

123,735

118,958

123,735

118,958

CURRENT ASSETS

Stocks

59,978

49,260

Debtors

6

1,355,827

1,361,417

Cash at bank

827,824

880,276

2,243,629

2,290,953

CREDITORS

Amounts falling due within one year

7

867,441

968,271

NET CURRENT ASSETS

1,376,188

1,322,682

TOTAL ASSETS LESS CURRENT LIABILITIES

1,499,923

1,441,640

CREDITORS

Amounts falling due after more than one year

8

949,581

976,802

NET ASSETS

550,342

464,838

CAPITAL AND RESERVES

Called up share capital

9

100

100

Retained earnings

10

550,242

464,738

SHAREHOLDERS' FUNDS

550,342

464,838

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 30 October 2025 and were signed by:

Mr S M Patel - Director

1.	STATUTORY INFORMATION

Naspram Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill

Goodwill, being the amount paid in connection with the acquisition of a business in 2011, is being amortised evenly over its estimated useful life of four years.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings

-

25% on reducing balance

Motor vehicles

-

25% on reducing balance

Computer equipment

-

25% on reducing balance

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 7 (2024 - 5 ) .

4.	INTANGIBLE FIXED ASSETS

Goodwill

£

COST

At 1 February 2024

and 31 January 2025

244,500

AMORTISATION

At 1 February 2024

and 31 January 2025

244,500

NET BOOK VALUE

At 31 January 2025

-

At 31 January 2024

-

5.	TANGIBLE FIXED ASSETS

Fixtures

and

Motor

Computer

fittings

vehicles

equipment

Totals

£

£

£

£

COST

At 1 February 2024

183,816

45,000

54,253

283,069

Additions

25,397

-

15,577

40,974

At 31 January 2025

209,213

45,000

69,830

324,043

DEPRECIATION

At 1 February 2024

108,742

39,541

15,828

164,111

Charge for year

25,118

1,365

9,714

36,197

At 31 January 2025

133,860

40,906

25,542

200,308

NET BOOK VALUE

At 31 January 2025

75,353

4,094

44,288

123,735

At 31 January 2024

75,074

5,459

38,425

118,958

6.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.1.25

31.1.24

£

£

Amounts owed by participating interests

1,318,396

1,323,396

Other debtors

37,431

38,021

1,355,827

1,361,417

Included within participated undertakings were loans due from PSM Portfolio Limited , Airspins Limited and Central Pharmaclinics Limited.

7.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.1.25

31.1.24

£

£

Trade creditors

304,205

281,818

Other creditors

6,976

11,479

Tax

33,851

38,447

Social security and other taxes

1,127

3,458

Pensions

358

358

Net wages

7,761

6,207

Directors' current accounts

326,070

393,467

Accruals and deferred income

187,093

233,037

867,441

968,271

8.

CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

31.1.25

31.1.24

£

£

Bank loan

949,581

976,802

9.	CALLED UP SHARE CAPITAL

Allotted and issued:

Number:

Class:

Nominal

31.1.25

31.1.24

value:

£

£

100

Ordinary shares

£1

100

100

10.

RESERVES

Retained

earnings

£

At 1 February 2024

464,738

Profit for the year

125,504

Dividends

(40,000

)

At 31 January 2025

550,242